Back to top
more

Cardlytics (CDLX)

(Delayed Data from NSDQ)

$1.30 USD

1.30
4,870,777

-0.46 (-26.14%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $1.32 +0.02 (1.54%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 246)

Industry: Technology Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Cardlytics (CDLX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of +18.75% and -0.86%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Blade Air Mobility, Inc. (BLDE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blade Air Mobility (BLDE) delivered earnings and revenue surprises of -25.00% and +10.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardlytics (CDLX) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

Cardlytics (CDLX) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Cardlytics (CDLX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 22.22% and 7.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Priority Technology (PRTH) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Priority Technology (PRTH) delivered earnings and revenue surprises of 10% and 1.63%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Arghyadeep Bose headshot

Coherent Stock Falls 22% in 6 Months: Is This a Buying Opportunity?

by Arghyadeep Bose

Given the dip in COHR shares, we assess its current position to determine whether investors should add it to their portfolio or refrain from doing so.

Zacks Equity Research

Cardlytics (CDLX) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 100% and 16.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Arghyadeep Bose headshot

Outbrain Stock Before Q4 Earnings: Smart Buy or a Risky Move?

by Arghyadeep Bose

Diversification in offerings is expected to have benefited OB's top line in the fourth quarter of 2024.

Arghyadeep Bose headshot

Parsons Stock Gains 49% in a Year: What Should Investors Do Now?

by Arghyadeep Bose

Given the recent rise in PSN shares, we analyze its current position to determine whether you should buy, hold or sell it.

Zacks Equity Research

Here Is Why Bargain Hunters Would Love Fast-paced Mover Cardlytics (CDLX)

by Zacks Equity Research

Cardlytics (CDLX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Cardlytics (CDLX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 54.55% and 19.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Jacobs Solutions (J) Q3 Earnings Beat Estimates

by Zacks Equity Research

Jacobs Solutions (J) delivered earnings and revenue surprises of 0.51% and 3.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardlytics (CDLX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 44.19% and 10.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Spotify (SPOT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Spotify (SPOT) delivered earnings and revenue surprises of -111.25% and 2.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardlytics (CDLX) Surges 13.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Cardlytics (CDLX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

CleanSpark (CLSK) Soars 8.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CleanSpark (CLSK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Is Cardlytics (CDLX) Stock Outpacing Its Business Services Peers This Year?

by Zacks Equity Research

Here is how Cardlytics (CDLX) and Trane Technologies (TT) have performed compared to their sector so far this year.

Zacks Equity Research

Does Cardlytics (CDLX) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 49.3% upside potential for Cardlytics (CDLX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Cardlytics (CDLX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 37.50% and 4.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardlytics (CDLX) Recently Broke Out Above the 200-Day Moving Average

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 200-day simple moving average?

Zacks Equity Research

Earnings Preview: NV5 Global (NVEE) Q1 Earnings Expected to Decline

by Zacks Equity Research

NV5 (NVEE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Cardlytics (CDLX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cardlytics (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cardlytics (CDLX) Soars 80.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Cardlytics (CDLX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Strength Seen in Symbotic Inc. (SYM): Can Its 9.5% Jump Turn into More Strength?

by Zacks Equity Research

Symbotic Inc. (SYM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Cardlytics (CDLX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 45.28% and 2.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?